Forma Therapeutics Holdings (FMTX) Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease

Go back to Forma Therapeutics Holdings (FMTX) Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease

Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease

November 10, 2020 7:05 AM EST

WATERTOWN, Mass.--(BUSINESS WIRE)-- Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the European Commission granted Orphan Drug designation to Formas FT-4202 for the treatment of sickle cell disease (SCD), based on a positive opinion... More